Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 3

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 2(4)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04706013Phase 3Recruiting

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

Role: lead

NCT01522417Phase 2Completed

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Role: lead

NCT00917293Phase 2Terminated

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

Role: lead

NCT01245725Phase 3Withdrawn

Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention

Role: lead

NCT01766154Phase 1Completed

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

Role: lead

NCT00402506Phase 3Completed

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

Role: lead

NCT00157729Phase 2Completed

MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)

Role: lead

NCT00157716Phase 2Completed

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

Role: lead

All 8 trials loaded